Multiple Sclerosis and the Spinal Cord

Neurologic Clinics

Volumn 31, Issue 1, 2013, Pages 55-77

  Sheremata, William ^a   Tornes, Leticia ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Clinically isolated syndrome; Disability; MRI; MS treatment; Multiple sclerosis; Spinal cord syndromes; Suspended sensory loss; Useless hand syndrome

Indexed keywords

4 AMINOPYRIDINE; AMANTADINE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BACLOFEN; BETA1A INTERFERON; BOTULINUM TOXIN A; CARBAMAZEPINE; CLONAZEPAM; CORTICOTROPIN; DANTROLENE; DIPEPTIDYL CARBOXYPEPTIDASE; DOUBLE STRANDED DNA ANTIBODY; FINGOLIMOD; GABAPENTIN; GLATIRAMER; INTERFERON BETA SERINE; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MITOXANTRONE; MODAFINIL; NATALIZUMAB; NORTRIPTYLINE; OXYBUTYNIN; PHENYTOIN; PROSTAGLANDIN E1; RITUXIMAB; SILDENAFIL; TIZANIDINE; UNINDEXED DRUG; VARDENAFIL;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ATAXIA; AUTOPSY; BACTERIAL INFECTION; BLADDER DYSFUNCTION; BREAST FEEDING; CATARACT; CELL INFILTRATION; CEREBROSPINAL FLUID ANALYSIS; COMMUNITY HOSPITAL; COMPUTER ASSISTED TOMOGRAPHY; DEMYELINATING DISEASE; DEMYELINATION; DIFFERENTIAL DIAGNOSIS; DISABILITY; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG MEGADOSE; DYSESTHESIA; EMOTIONAL DISORDER; ERECTILE DYSFUNCTION; EVOKED VISUAL RESPONSE; FATIGUE; FOLLOW UP; GANGRENE; GOLD STANDARD; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INTERMITTENT CATHETERIZATION; JOINT NECROSIS; LIMB WEAKNESS; LOW DRUG DOSE; LUMBAR PUNCTURE; MEDICAL HISTORY; MENTAL DISEASE; MOOD DISORDER; MULTIPLE SCLEROSIS; MUSCLE RIGIDITY; MYCOSIS; MYELITIS; MYELOOPTIC NEUROPATHY; NEUROLOGIC EXAMINATION; NOCTURIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; PAIN; PARAPLEGIA; PARASITOSIS; PARESTHESIA; PAROXYSMAL DYSTONIA; PATHOPHYSIOLOGY; PLASMAPHERESIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SARCOIDOSIS; SELF EMPLOYMENT; SEXUAL DYSFUNCTION; SHOULDER PAIN; SJOEGREN SYNDROME; SPASTICITY; SPINAL CORD LESION; URINE RETENTION; USELESS HAND SYNDROME; VIRUS INFECTION; VISUAL IMPAIRMENT; WEAKNESS; WHEELCHAIR;

DIAGNOSIS, DIFFERENTIAL; HUMANS; MULTIPLE SCLEROSIS; SPINAL CORD; SPINAL CORD DISEASES;

EID: 84870190955     PISSN: 07338619     EISSN: 15579875     Source Type: Journal    
DOI: 10.1016/j.ncl.2012.09.007     Document Type: Review

References (82)

1. McAlpine's multiple sclerosis 2006, Churchill Livingston Elsevier, London. 4th edition. A. Compston, C. Confavreux, H. Lassmann (Eds.).
2. Multiple sclerosis, foreword. Neurol Clin 1983, vol. 1. WB Saunders, Philadelphia.
3. Multiple sclerosis. foreword. Neurol Clin 1995, vol. 13. WB Saunders, Philadelphia, Number 1.
4. Weinshenker B.G., Bass B., Rice G.P., et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989, 112(Pt 1):133-146.
5. Thompson A.J., Polman C.H., Miller D.H., et al. Primary progressive multiple sclerosis. Brain 1997, 120(Pt 6):1085-1096.
6. Noseworthy J.H., Lucchinetti C., Rodriguez M., et al. Multiple sclerosis. N Engl J Med 2000, 343(13):938-952. 10.1056/NEJM200009283431307.
7. Charcot J.M. Lectures on the diseases of the nervous system delivered at La Salpêtrière 1877, The New Sydenham Society, London, [Sigerson G, Trans.].
8. Cruveilhier J. Anatomie pathologique du corps humain 1849, J. B. Bulleire, Paris, p. 1829-42.
9. Young I.R., Hall A.S., Pallis C.A., et al. Nuclear magnetic resonance imaging of the brain in multiple sclerosis. Lancet 1981, 2(8255):1063-1066.
10. Poser C.M., Presthus J., Hoersdal O. Clinical characteristics of autopsy-proved multiple sclerosis. Neurology 1966, 16:791.
11. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33(11):1444-1452.
12. Lumsden C. The neuropathy of multiple sclerosis. Handbook of clinical neurology 1970, 277-305. Elsevier, New York. P. Vincent, G. Bruyn (Eds.).
13. Powell H.C., Lampert P.W. Pathology of multiple sclerosis. Neurol Clin 1983, 1:631-644. WB Saunders, Philadelphia.
14. Lassmann H., Wekerle H. The pathology of multiple sclerosis. McAlpine's multiple sclerosis 2006, 567-599. Churchill Livingston Elsevier, London. 4th edition. A. Compston, C. Confavreux, H. Lassmann (Eds.).
15. Trapp B.D., Peterson J., Ransohoff R.M., et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998, 338(5):278-285. 10.1056/NEJM199801293380502.
16. Frohman E.M., Wingerchuk D.M. Clinical practice. Transverse myelitis. N Engl J Med 2010, 363(6):564-572. 10.1056/NEJMcp1001112.
17. Waxman S.G. Membranes, myelin, and the pathophysiology of multiple sclerosis. N Engl J Med 1982, 306(25):1529-1533. 10.1056/NEJM198206243062505.
18. Goodman A.D., Brown T.R., Edwards K.R., et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010, 68(4):494-502. 10.1002/ana.22240.
19. Schumacher G.A., Beebe G., Kibler R.F., et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci 1965, 122:552-568.
20. Poser C.M., Paty D.W., Scheinberg L., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983, 13(3):227-231. 10.1002/ana.410130302.
21. McDonald W.I., Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001, 50(1):121-127.
22. Polman C.H., Reingold S.C., Edan G., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria" Ann Neurol 2005, 58(6):840-846. 10.1002/ana.20703.
23. Polman C.H., Reingold S.C., Banwell B., et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011, 69(2):292-302. 10.1002/ana.22366.
24. Dale R.C., de Sousa C., Chong W.K., et al. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 2000, 123(Pt 12):2407-2422.
25. de Seze J., Stojkovic T., Breteau G., et al. Acute myelopathies: clinical, laboratory and outcome profiles in 79 cases. Brain 2001, 124(Pt 8):1509-1521.
26. Wingerchuk D.M., Lennon V.A., Pittock S.J., et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66(10):1485-1489. 10.1212/01.wnl.0000216139.44259.74.
27. Jacob A., Weinshenker B.G., Violich I., et al. Treatment of neuromyelitis optica with rituximab retrospective analysis of 25 patients. Arch Neurol 2008, 65:1443-1448.
28. Bedi G.S., Brown A.D., Delgado S.R., et al. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 2011, 17:1225-1230.
29. Iannuzzi M.C., Rybicki B.A., Teinstein A.S. Sarcoidosis. N Engl J Med 2007, 357:2153-2165.
30. Berger J.R., Sheremata W.A., Resnick L., et al. Multiple sclerosis like illness associated with human immunodeficiency virus infection. Neurology 1989, 39:324-329.
31. Sheremata W.A., Berger J.R., Harrington W., et al. Human lymphotropic (HTLV-1) associated myelopathy: a report of ten cases born in the United States. Arch Neurol 1992, 49:1113-1118.
32. Sheldon J.J., Siddarthan R., Tobias J., et al. MR imaging of multiple sclerosis: comparison with clinical, paraclinical, laboratory, and CT examinations. Am J Neuroradiol 1985, 6:663-669.
33. Honig H.S., Sheremata W.A. Magnetic resonance imaging of spinal cord lesions in multiple sclerosis. J Neurol Neurosurg Psychiatry 1989, 52:459-466.
34. Thorpe J.W., Kidd D., Moseley I.F., et al. Spinal MRI in patients with suspected multiple sclerosis and negative brain MRI. Brain 1996, 119:709-714.
35. Debette S., de Seze J., Pruvo J.-P., et al. Long-term outcome of acute and subacute myelopathies. J Neurol 2009, 256:980-988.
36. Miller D.H., McDonald W.I., Blumhardt I.D., et al. Magnetic resonance imaging in noncompressive spinal cord syndromes. Ann Neurol 1987, 22:714-725.
37. O'Riordan J.I., Thompson A.J., Kingsley D.P., et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 1998, 121:495-505.
38. Brex P.A., Ciccarelli O., O'Riordan R., et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002, 346:158-164.
39. Fisniku L.K., Brex P.A., Altmann D.R., et al. Disability and T2 MRI lesions: a 20 year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008, 131:808-817.
40. O'Connor P., Miller D.H., Riester K., et al. Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis. Mult Scler 2005, 11:565-572. International Natalizumab Trial Group.
41. Scott T.F., Frohman E.M., De Seze J., et al. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the therapeutic and technology assessment subcommittee of the American Academy of Neurology. Neurology 2011, 77:2128-2134.
42. Lhermitte J., Dollak I., Nicolas M. Les douleurs a type de decharge electrique consecutives a la flexion cephalique dans la sclerose en plaques. Rev Neurol 1924, 31:56.
43. Coleman R.J., Russon L., Currie S. Useless hand of Oppenheim - magnetic resonance imaging findings. Postgrad Med J 1993, 69:149-150.
44. Jacobs I., Kinkel D.R., Kinkel W.R. Silent brain lesions in patients with isolated idiopathic optic neuritis. A clinical and nuclear magnetic resonance imaging study. Arch Neurol 1986, 43:452-455.
45. Ormerod I.E., McDonald W.I., de Boulay G.H., et al. Disseminated lesions at presentation in patients with optic neuritis. J Neurol Neurosurg Psychiatry 1986, 49:124-127.
46. Mathews W.B. Tonic seizures in disseminated sclerosis. Brain 1958, 81:193-206.
47. Usmani N., Bedi G., Lam B.L., et al. Association between paroxysmal tonic spasms and neuromyelitis optica. Arch Neurol 2012, 69:121-124.
48. Kim S.M., Go M.J., Sung J.J., et al. Painful tonic spasm in neuromyelitis optica. Arch Neurol 2012, 69(8):1026-1031.
49. Rose A.S., Kuzma J.W., Kurtzke J.F., et al. Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo-final report. Neurology 1970, 20(5):1-59.
50. Cree B. Neuromyelitis optica: diagnosis, pathogenesis and treatment. Curr Neurol Neurosci Rep 2008, 8(5):427-433.
51. Stanbury R.M., Graham E.M. Systemic corticosteroid therapy-side effects and their management. Br J Ophthalmol 1998, 82(6):704-708.
52. Weinshenker B.G., O'Brien P.C., Petterson T.M., et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999, 46(6):878-886.
53. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. 1. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993, 43:655-661.
54. Paty D.W., Li K.D. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993, 42:662-667. UBC MS/MRI Group and the IFN Multiple Sclerosis Study Group.
55. Jacobs L.D., Cookfair D.L., Rudick R.A., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996, 39:285-294.
56. Rudick R.A., Goodkin D.E., Jacobs L.D., et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. Neurology 1997, 49:358-363.
57. Johnson K.P., Brooks B.R., Cohen J.A., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995, 45:1268-1276.
58. Johnson K.P., Brooks B.R., Ford C.C., et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Mult Scler 2000, 6:255-266.
59. PRISMS (Prevention of Relapses and Disability by Interferon b-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomized double-blind placebo-controlled study of interferon b-1a in relapsing/remitting multiple sclerosis. Lancet 1998, 352:1498-1504.
60. Panitch H., Goodin D.S., Francis G., et al. Randomized, comparative study of interferon β-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 2002, 59:1496-1506.
61. Lublin F. AAN presentation of the CombiRx study. AAN abstract book. San Diego (CA); 2012.
62. Miller D., Barkhof F., Montalban X., et al. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005, 4(5):281-288. 10.1016/S1474-4422(05)70071-5.
63. Coyle P.K. Early treatment of multiple sclerosis to prevent neurologic damage. Neurology 2008, 71(Suppl 3):53-57.
64. Jacobs L.D., Beck R.W., Simon J.H., et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS study group. N Engl J Med 2000, 343(13):898-904. 10.1056/NEJM200009283431301.
65. Comi M., Filippi F., Barkhof L., et al. Effect of early interferon treatment on conversion to definite multiple sclerosis; a randomised study. Lancet 2001, 357:1576-1582. Hommes and the Early Treatment of MS Study Group.
66. Comi G., De Stefano N., Freedman M.S., et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol 2012, 11:33-41.
67. Kappos L., Polman C.H., Freedman M.S., et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006, 67:1242-1249. BENEFIT Study Group.
68. Comi G., Martinelli V., Rodegher M., et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009, 374(9700):1503-1511. 10.1016/S0140-6736(09)61259-9.
69. Polman C.H., O'Connor P.W., Havrdova E., et al. A randomized, placebo-controlled trial of natalizumab for relapsing remitting multiple sclerosis. N Engl J Med 2006, 334:899-910.
70. Bloomgren G., Richman S., Hotermans C., et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012, 366:1870-1880.
71. Fox R.J., Rudick R.A. Risk stratification and patient counseling in natalizumab in multiple sclerosis. Neurology 2012, 78:436-437.
72. Cohen J.A., Barkhof F., Comi G., et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010, 362(5):402-415. 10.1056/NEJMoa0907839.
73. Kappos L., Radue E.W., O'Connor P., et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010, 362(5):387-401. 10.1056/NEJMoa0909494.
74. Cohen J.A., Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol 2011, 69(5):759-777. 10.1002/ana.22426.
75. Schwid S.R., Covington M., Segal B.M., et al. Fatigue in multiple sclerosis: current understanding and future directions. J Rehabil Res Dev 2002, 39:211-224.
76. DasGupta R., Fowler C.J. Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies. Drugs 2003, 63(2):153-166.
77. De Ridder D., Ost D., Van der Aa F., et al. Conservative bladder management in advanced multiple sclerosis. Mult Scler 2005, 11(6):694-699.
78. Cvetkovic R.S., Plosker G.L. Desmopressin: in adults with nocturia. Drugs 2005, 65(1):99-107. [discussion: 108-9].
79. Motl R.W., Smith D.C., Elliot J., et al. Combined training improves walking mobility in persons with significant disability from multiple sclerosis: a pilot study. J Neurol Phys Ther 2012, 36:32-37.
80. Goodman A.D., Brown T.R., Krupp L.B., et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009, 373(9665):732-738. 10.1016/S0140-6736(09)60442-6.
81. Rizzo M.A., Hadjimichael O.C., Preiningerova J., et al. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 2004, 10(5):589-595.
82. Feldman R.G., Kelly-Hayes M., Conomy J.P., et al. Baclofen for spasticity in multiple sclerosis. Double-blind crossover and three-year study. Neurology 1978, 28(11):1094-1098.